InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration ...
Bausch + Lomb acquired Whitecap Biosciences, including its two therapies for potential use in glaucoma and geographic atrophy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback